In vitro and in vivo efficacy of β-lactams against replicating and slowly growing/nonreplicating Mycobacterium tuberculosis.
about
Can we prevent antimicrobial resistance by using antimicrobials better?Unravelling the Secrets of Mycobacterial Cidality through the Lens of AntisenseRapid cytolysis of Mycobacterium tuberculosis by faropenem, an orally bioavailable β-lactam antibiotic.Pharmacokinetic and pharmacodynamic evaluation of AZD5847 in a mouse model of tuberculosis.1,4-azaindole, a potential drug candidate for treatment of tuberculosis.Carbapenems and Rifampin Exhibit Synergy against Mycobacterium tuberculosis and Mycobacterium abscessus.Identification of Mycobacterial Genes Involved in Antibiotic Sensitivity: Implications for the Treatment of Tuberculosis with β-Lactam-Containing Regimens.Syntheses and Biological Evaluations of Highly Functionalized Hydroxamate Containing and N-Methylthio Monobactams as Anti-Tuberculosis and β-Lactamase Inhibitory Agents.A Faropenem, Linezolid, and Moxifloxacin Regimen for Both Drug-Susceptible and Multidrug-Resistant Tuberculosis in Children: FLAME Path on the Milky Way.Optimal Clinical Doses of Faropenem, Linezolid, and Moxifloxacin in Children With Disseminated Tuberculosis: Goldilocks.Osmosensory signaling in Mycobacterium tuberculosis mediated by a eukaryotic-like Ser/Thr protein kinase.Nucleoside analogs and tuberculosis: new weapons against an old enemy.β-Lactam Resistance Mechanisms: Gram-Positive Bacteria and Mycobacterium tuberculosis.Adverse effects of oral second-line antituberculosis drugs in children.An Update on Repurposed Medications for the Treatment of Drug-Resistant Tuberculosis.Mutation in an Unannotated Protein Confers Carbapenem Resistance in Mycobacterium tuberculosis.Targeting Phenotypically Tolerant Mycobacterium tuberculosis.Bactericidal activity and mechanism of action of AZD5847, a novel oxazolidinone for treatment of tuberculosis.In vitro and in vivo activity of biapenem against drug-susceptible and rifampicin-resistant Mycobacterium tuberculosis.Efficacy of β-lactam/β-lactamase inhibitor combination is linked to WhiB4-mediated changes in redox physiology of Mycobacterium tuberculosis.Recognizing drug targets using evolutionary information: implications for repurposing FDA-approved drugs against Mycobacterium tuberculosis H37Rv.In vitro susceptibility of Mycobacterium tuberculosis isolates to an oral carbapenem alone or in combination with β-lactamase inhibitorsSusceptibilities of MDR Mycobacterium tuberculosis isolates to unconventional drugs compared with their reported pharmacokinetic/pharmacodynamic parameters.
P2860
Q26829707-56A62B25-9539-45D3-BD27-7F617AF2B03EQ28551800-10C740F4-A8C9-45F9-BF49-52D3BCAD108EQ30620897-BF9176EB-0F63-485D-9848-BB5F2AA69DF2Q33798492-B00166C5-63B4-45C3-86D4-29245DB2ED99Q34057555-CC204F6F-F146-4E05-AFBA-4442C13E3A51Q36075809-74ABC127-989A-4924-816D-1AA2744024CBQ36355735-8FC6DD27-AE4E-498B-9D81-F0A1DC62540FQ36603702-FAF0FE10-A0A4-4A08-92D1-A8A303FAA15AQ37339279-71529BC9-BB8F-4E55-8003-709F7177425DQ37339290-23D90D77-23CE-4519-BA6D-4CC86CE2408BQ37421344-193425D3-C5D7-4052-8571-7554D76A931DQ38397331-747D4CB2-CC0A-4AF4-9B1E-7164F307C06EQ38811605-48998277-D827-4357-9654-CB6680021B61Q38837774-8AC97C68-FF9F-426C-B338-44B8727C94BFQ38885365-9D482D01-835D-4814-95E1-E2E51E364765Q39030679-09CBF411-222B-4286-82FE-3F1BA46876C4Q39149038-83E354F2-7764-4C2D-879A-6D80A9E406B2Q39321112-E3B84DBE-9D96-441F-A9AB-311A3A6C5987Q40187337-DE0FFC76-70F2-4F58-B735-B75890A56C05Q40197457-4859746E-EDAD-4AB9-AA17-6E1566C4B2E0Q40475389-436220D6-7677-4505-96CB-2473468F4724Q42109610-09191C5E-91CC-44CE-B961-8CBA82F8EC1CQ50780166-7B108C93-AECC-4F4C-B42C-6FA451138449
P2860
In vitro and in vivo efficacy of β-lactams against replicating and slowly growing/nonreplicating Mycobacterium tuberculosis.
description
article científic
@ca
article scientifique
@fr
articolo scientifico
@it
artigo científico
@pt
bilimsel makale
@tr
scientific article published on 18 March 2013
@en
vedecký článok
@sk
vetenskaplig artikel
@sv
videnskabelig artikel
@da
vědecký článek
@cs
name
In vitro and in vivo efficacy ...... ng Mycobacterium tuberculosis.
@en
In vitro and in vivo efficacy ...... ng Mycobacterium tuberculosis.
@nl
type
label
In vitro and in vivo efficacy ...... ng Mycobacterium tuberculosis.
@en
In vitro and in vivo efficacy ...... ng Mycobacterium tuberculosis.
@nl
prefLabel
In vitro and in vivo efficacy ...... ng Mycobacterium tuberculosis.
@en
In vitro and in vivo efficacy ...... ng Mycobacterium tuberculosis.
@nl
P2093
P2860
P356
P1476
In vitro and in vivo efficacy ...... ng Mycobacterium tuberculosis.
@en
P2093
Deepa Bhattacharjee
Jitendar Reddy
K G Vishwas
Manish Parab
Meenakshi Balganesh
Naveen Kumar
Neela Dinesh
Radha Shandil
Samit Ganguly
Sreevalli Sharma
P2860
P304
P356
10.1128/AAC.00023-13
P407
P577
2013-03-18T00:00:00Z